Bob Li: It was a privilege to lead the first international clinical trial to crack KRAS
Bob Li, Chief Scientific Officer of MSK Direct at Memorial Sloan Kettering Cancer Center, shared on LinkedIn:
“It was a privilege to lead the first international clinical trial to crack KRAS, drugging the undruggable King of Oncogenes in human cancers. However, the enemy remains formidable, and we are also just getting warmed up.
It is an honor working with Dr. O’Reilly and Dr. Singhal at Memorial Sloan Kettering Cancer Center in publishing this piece in Nature Medicine that outlines the strategic thinking and future directions in the KRAS battle. Combination therapies against KRAS are underway, and first-in-human clinical trials of new allele specific molecules are already here, including promising inhibitors of KRAS G12D.
Apart from furthering our advances against lung cancers, we have a comprehensive plan to beat some of the most recalcitrant malignancies – yes pancreatic cancer you have been put on notice!
This is achievable in this lifetime only through international collaboration.”
Authors: Anupriya Singhal, Bob Li and Eileen O’Reilly
Source: Bob Li/LinkedIn
